{
    "Trade/Device Name(s)": [
        "First Sign Drug Of Abuse Cup Test",
        "First Sign Drug Of Abuse Dip Card Test"
    ],
    "Submitter Information": "W.H.P.M., Inc.",
    "510(k) Number": "K150162",
    "Predicate Device Reference 510(k) Number(s)": [
        "K052115"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LAF",
        "JXM",
        "DJG"
    ],
    "Summary Letter Date": "January 19, 2015",
    "Summary Letter Received Date": "January 26, 2015",
    "Submission Date": "February 24, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.3610",
        "21 CFR 862.3170",
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Methamphetamine test system",
        "Benzodiazepine test system",
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Oxazepam",
        "Methamphetamine",
        "Morphine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Urine cup",
        "Dip Card"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow chromatographic immunoassay"
    ],
    "Methodologies": [
        "Competitive binding immunoassay",
        "Lateral flow"
    ],
    "Submission Type(s)": [
        "Kit",
        "Test Device"
    ],
    "Document Summary": "FDA 510(k) summary for First Sign Drug of Abuse Cup and Dip Card Tests for qualitative detection of oxazepam, methamphetamine, and morphine in human urine",
    "Indications for Use Summary": "Qualitative determination of oxazepam, methamphetamine, and morphine in human urine at specified cutoff concentrations using a cup or dip card format; for in vitro diagnostic, over-the-counter, and prescription use",
    "fda_folder": "Toxicology"
}